MWC
VRTX icon

MBM Wealth Consultants’s Vertex Pharmaceuticals VRTX Stock Holding History

MBM Wealth Consultants’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.36M Buy
4,750
+600
+14% +$266K 0.46% 29
2026
Q1 		$1.85M Buy
4,150
+225
+6% +$105K 0.43% 32
2025
Q4 		$1.78M Buy
3,925
+275
+8% +$119K 0.42% 33
2025
Q3 		$1.43M Buy
3,650
+775
+27% +$324K 0.35% 47
2025
Q2 		$1.28M Buy
2,875
+103
+4% +$47.5K 0.34% 47
2025
Q1 		$1.34M Buy
2,772
+108
+4% +$50.3K 0.4% 41
2024
Q4 		$1.08M Buy
2,664
+124
+5% +$57.5K 0.32% 48
2024
Q3 		$1.18M Buy
2,540
+159
+7% +$76.4K 0.37% 46
2024
Q2 		$1.16M Sell
2,381
-69
-3% -$29.9K 0.39% 42
2024
Q1 		$1.02M Buy
2,450
+82
+3% +$34.7K 0.36% 46
2023
Q4 		$1.03M Buy
2,368
+89
+4% +$32.9K 0.39% 40
2023
Q3 		$846K Buy
2,279
+81
+4% +$28.3K 0.37% 42
2023
Q2 		$761K Buy
2,198
+417
+23% +$141K 0.33% 46
2023
Q1 		$649K Hold
1,781
– – 0.26% 48
2022
Q4 		$509K Buy
1,781
+681
+62% +$208K 0.24% 56
2022
Q3 		$327K Sell
1,100
-162
-13% -$46.6K 0.16% 62
2022
Q2 		$356K Buy
1,262
+48
+4% +$12.8K 0.17% 62
2022
Q1 		$317K Sell
1,214
-34
-3% -$8.07K 0.13% 79
2021
Q4 		$274K Buy
1,248
+120
+11% +$23.3K 0.11% 84
2021
Q3 		$205K Buy
1,128
+154
+16% +$30.1K 0.09% 97
2021
Q2 		$197K Buy
974
+158
+19% +$33K 0.09% 98
2021
Q1 		$175K Buy
816
+233
+40% +$51.2K 0.09% 98
2020
Q4 		$138K Buy
+583
New +$134K 0.08% 97

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

MBM Wealth Consultants's VRTX Position: Q2 2026 in Review

MBM Wealth Consultants increased its Vertex Pharmaceuticals (VRTX) stake by 14% in Q2 2026, buying an estimated $266K and bringing the position to 4,750 shares worth $2.36M. The position accounts for 0.46% of the portfolio, ranked #29.

MBM Wealth Consultants first reported a position in VRTX in Q4 2020 and has held it in 23 quarters since. 728 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • MBM Wealth Consultants held 4,750 shares of Vertex Pharmaceuticals worth $2.36M as of Q2 2026.
  • MBM Wealth Consultants bought 600 Vertex Pharmaceuticals shares in Q2 2026, an estimated $266K.
  • Vertex Pharmaceuticals made up 0.46% of MBM Wealth Consultants's portfolio in Q2 2026, its #29 holding.
  • MBM Wealth Consultants first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • 728 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on MBM Wealth Consultants's 13F filing for Q2 2026, filed 24 Jul 2026.